Home/Filings/4/0000899243-23-016413
4//SEC Filing

Northpond Ventures, LP 4

Accession 0000899243-23-016413

CIK 0001645569other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 5:36 PM ET

Size

15.0 KB

Accession

0000899243-23-016413

Insider Transaction Report

Form 4
Period: 2023-06-22
Transactions
  • Sale

    Common Stock

    2023-06-22$46.50/sh523,503$24,342,890166,293 total(indirect: By: Northpond Ventures II, LP)
  • Sale

    Common Stock

    2023-06-22$46.50/sh1,969,368$91,575,612633,707 total(indirect: By: Northpond Ventures, LP)
Transactions
  • Sale

    Common Stock

    2023-06-22$46.50/sh1,969,368$91,575,612633,707 total(indirect: By: Northpond Ventures, LP)
  • Sale

    Common Stock

    2023-06-22$46.50/sh523,503$24,342,890166,293 total(indirect: By: Northpond Ventures II, LP)
Transactions
  • Sale

    Common Stock

    2023-06-22$46.50/sh1,969,368$91,575,612633,707 total(indirect: By: Northpond Ventures, LP)
  • Sale

    Common Stock

    2023-06-22$46.50/sh523,503$24,342,890166,293 total(indirect: By: Northpond Ventures II, LP)
Transactions
  • Sale

    Common Stock

    2023-06-22$46.50/sh1,969,368$91,575,612633,707 total(indirect: By: Northpond Ventures, LP)
  • Sale

    Common Stock

    2023-06-22$46.50/sh523,503$24,342,890166,293 total(indirect: By: Northpond Ventures II, LP)
Transactions
  • Sale

    Common Stock

    2023-06-22$46.50/sh1,969,368$91,575,612633,707 total(indirect: By: Northpond Ventures, LP)
  • Sale

    Common Stock

    2023-06-22$46.50/sh523,503$24,342,890166,293 total(indirect: By: Northpond Ventures II, LP)
Footnotes (3)
  • [F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $46.44 to $46.63, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F2]Northpond Ventures GP, LLC ("Northpond GP LLC") is the general partner of Northpond Ventures, LP ("Northpond Fund"), and Michael P. Rubin is the managing member of Northpond GP LLC. As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
  • [F3]Northpond Ventures GP II, LLC ("Northpond GP II LLC") is the general partner of Northpond Ventures II, LP ("Northpond Fund II"), and Michael P. Rubin is the managing member of Northpond GP II LLC. As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.

Issuer

DICE Therapeutics, Inc.

CIK 0001645569

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001867472

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 5:36 PM ET
Size
15.0 KB